Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tezepelumab in moderate to very severe COPD
NCT04039113Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2019
- Primary completion
- Nov 2023
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
A Phase 2 trial of tezepelumab in chronic obstructive pulmonary disease (COPD), sponsored by AstraZeneca. Started Jul 2019; status: completed.
02
Drugs
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT04039113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04039113.